Abstract: Ribonucleotide Reductase (RNR) plays a critical role in DNA synthesis, and is a well-recognized target for cancer chemotherapeutic and antiviral agents. RNR inhibition precludes DNA transcription and repair, from which results cell apoptosis. Many regulation checkpoints concerning RNR activity have been unravelled through the last two decades, with potential use to inhibit enzyme activity. This was accomplished by researchers from different but complementary areas, and from which several and different inhibitors have resulted. The volume of these studies has generated over 4000 articles since the discovery of RNR in 1960.
INTRODUCTION
Ribonucleotide reductase (RNR) is a ubiquitous radicalcontaining enzyme, which belongs to a small family of enzymes that are involved in the conversion of both purine and pyrimidines ribonucleotides diphosphates into their corresponding deoxyribonucleotides. Ribonucleotide reductase is the name by which the enzyme is normally referred to but its systematic name is 2'-deoxyribonucleoside-diphosphate: thioredoxin-disulfide 2'-oxidoreductase.
The reaction catalysed by RNR involves the replacement of the C2'-hydroxyl group on the ribose moiety by a hydrogen atom. After phosphorylation, the resulting molecules are the precursors needed for both synthesis and repair of the deoxyribonucleic acid (DNA). In each turnover the reductive potential ultimately comes from NADH, and intermediately by reductants such as thioredoxin (Scheme 1).
The key reaction catalysed by RNR makes it an attractive target to promote programmed cell death (apoptosis), either by inhibiting DNA repair or precluding DNA replication that hinders cell proliferation. Its inhibition and the resulting events have been primarily a target for therapeutic intervention for a number of human diseases, in which cell proliferation is abnormal and responsible for pathological diseases, such as anti-tumor, anti-viral and anti-bacterial therapies.
The first reports related with deoxyribose synthesis from ribose precursors date from 1953 when Rose et al. [1] studied the metabolism of C14-labeled cytidine in rats. The dCTP recovered from the rats DNA encouraged the occurrence of a reaction that allowed the conversion of *Address correspondence to this author at the REQUIMTE / Faculdade de Ciências do Porto, Rua Campo Alegre, 687, 4169-007 Porto, Portugal; Tel: 351-22 340 14 00; Fax: 351-22 200 86 28; E-mail: nscerque@fc.up.pt ribonucleotides into deoxyribonucleotides. Although the enzyme was still not known, this fact encouraged many scientists to find out the way by which each cell was able to produce deoxyribonucleotides. In 1961, the discovery of the enzyme ribonucleotide reductase, responsible for the reduction of ribonucleotides into deoxyribonucleotides, was reported by Peter Reichard [2] . The first enzyme was discovered in E. coli but later on it was found in all growing cells of every living organism and even several species of viruses carry their own copy of RNR [3] .
The volume of data currently available on RNR allows the research community to understand the involvement of this enzyme in the cell machinery and the associated checkpoints. The number of articles published till 2005 has already overcome 4000, and it can be observed in figure 1 that a great boost was given by Nordlund et al. [4] in 1990 when the three-dimensional structure of the enzyme was depicted. Currently, the number of published articles is still high which indicates the importance of the enzyme.
It is now clear that there are many regulation levels in the ribonucleotide reductase activity, and although the structure, catalytic and several inhibitory mechanisms have already been unraveled, many other important questions still remain unanswered.
In this review, a detailed overview of the enzyme is presented. The document has been divided into three main sections that try to summarize the background of RNR biochemistry as well as its mechanism of action and enzyme inhibition. The first section gives a general overview of all RNRs including their division into three classes, and special attention is given to the biochemistry and mechanism of action of class I. In the second section, RNR inhibition is reviewed in detail and the inhibitors have been divided into two main groups according to their mechanism of action, i.e. the inhibitors that preclude the formation of an active RNR and the inhibitors that once RNR is active preclude its activity. In each group, the inhibitors are grouped into several classes and when appropriate the corresponding patents and currently undergoing clinical trials are discussed. The final section gives the current opinion of the authors concerning the current and future developments of RNR taking into account the discussed data.
Classes of RNR
A number of RNRs of different species have already been disclosed, pointing to a common radical-based reaction mechanism [5] . Intriguingly, despite their central and common metabolic functions, these enzymes have different amino acid sequences, metallic cofactors, substrate specificity and reducing equivalents to accomplish the same chemistry. Their classification into three classes was based on the quaternary structure and activation mechanisms ( Table 1 ).
All RNR enzymes contain two components: a radical generator and a reductase [6] . These components can be located in different subunits or in the same one. The radical generator, the place where the radical is produced and stored, is not the same within all the RNR enzymes and is deeply buried inside the protein, in order to be protected from the environment. The reductase component is somewhat similar between all RNR classes and is where the reduction takes place. It is believed that upon substrate binding, the radical is transferred through a net of hydrogen atoms to the active site, where it is used to oxidize the substrate to a radical form that is followed by the reduction of the substrate at C2ṕ osition.
Class I RNRs are found in both prokaryotes and eukaryotes with few exceptions. They are characterized by a tyrosyl radical that is stabilized by an oxo-bridged binuclear Fe(III) complex and requires oxygen for its generation. The enzyme is a holoenzyme α2 β2 (Fig. 2) , being the R1 protein composed by two identical monomers (761 residues per monomer) each one lodging one active site (for reduction of purines and pyrimidines), constituted by five conserved residues, Cys439, Cys225, Cys462, Glu441 and Asn437, and three independent allosteric sites named s-site (specificity site), a-site (adenine specific site) and h-site (hexamerization site) that control the activity of the enzyme. The other dimer β 2 , named R2 has 375 residues in each monomer, each one containing a stable neutral tyrosyl free radical at position 122, coupled to a binuclear iron (Fe 2 O 2 ) cluster required for generation and stabilization of the radical. The X-ray structures of each subunit have already been determined [7] . Class II RNRs are restricted to prokaryotes (both aerobic and anaerobic) and use adenosylcobalamine to generate a free radical. In this class of enzymes the radical generator and a reductase are located in the same subunit, and α or α 2 proteins can be found. The radical is produced by adenosylcobalamin.
Class III RNRs, only function in anaerobic conditions and require a glycyl radical that is generated by a process that involves a [4Fe-4S] cluster and an S-adenosyl methionine. The α 2 dimer is the active form and contains the active glycyl radical and the binding sites for the aerobic reductases. The β 2 subunit is a small iron sulfur containing protein, which is essential for glycyl radical production.
It is interesting to note that despite the large differences between RNR classes, the common catalytic and similar allosteric mechanisms, as well as retention of critical residues in the protein sequence, suggest similar structures. Although these facts indicate a common origin of RNR during evolution, this subject is still under discussion and recently it was found that some organisms contain genes that encode different reductases [8] .
As the aerobic bacteria E. coli RNR is the archetype for all Class Ia ribonucleotide diphosphate reductase and as it serves as a prototype for the mammalian protein, we will dedicate the rest of this review to this class of enzymes. Therefore, whenever RNR is mentioned in the review it is linked to the enzymes of class Ia otherwise it will be specifically mentioned in the text.
RNR Regulation
The levels and activity of RNR are highly regulated by the cell cycle and DNA checkpoints which maintain optimal dNTP pools required for genetic fidelity. The enzyme can be regulated by two factors: by transcription of the genes or by allosteric control of RNR by triphosphate effectors.
The genes of each subunit are located on separate chromosomes and the corresponding mRNAs are similarly expressed during the S-Phase of the cell cycle. During the normal cell cycle the levels of the R1 protein do not appear to change substantially and can be detected throughout the whole cycle. In contrast, protein R2 can only be truly detected between the S phase, where it slowly accumulates, up to late mitosis, where it is rapidly degraded. This mechanism ensures an adequate supply of dNTPs for replication and/or repair during the S and G2 phase of the cell cycle (Fig. 3) . What appends next, during the remaining phases of the cell cycle is still obscure. In fact, the absence of protein R2 during the G1 phase would lead to the inactivation of protein R1 which precludes the formation of the necessary dNTPs for DNA repair. Some light into these aspects was added by Guittet et al. [9] , who found that when DNA damage occurs, a transcriptional induction of a new protein called p53R2 (regulated by p53 [9, 10] ) is observed. This study demonstrated that protein R1 can form a functional complex either with protein R2 or protein p53R2. It is believed that such induction is activated by the cell cycle checkpoints ATM/ATR and CHK2 that promotes the increase of the RNR activity in order to prevent DNA Fig. (3) . Schematic figure displaying the levels of the R1 and R2 protein throughout the cell cycle (R1 protein in green and protein R2 in blue).
damage. Accordingly, R2 protein appears to be responsible for the maintenance of dNTPs levels for replication, whereas p53R2 is responsible for production of dNTPs is response to DNA damage [11] . It can therefore be expected that blocking of p53R2 in cases of highly malignant cancer with resistance to anti-cancer agents and radiation therapy would be a highly effective treatment with few side-effects. Moreover, because p53R2 may act as a homodimer (as R2 does), it might be possible to confer a dominant negative effect and suppress the activity of the enzyme by introducing mutated p53R2 genes or p53R2 protein into cancer cells, so both mutated p53R2 genes and p53R2 protein should be useful as therapeutic agents for highly malignant cancers with resistance to anti-cancer agents and radiation therapy. In addition, investigation of mutations to this gene should be useful in cancer diagnosis and prevention [12] .
It has been reported also that the binding requirements of R1 for more than one radical generator complex may explain the nature of the uncoupled expression of proteins R1 and R2 (R1 gene is located at chromosome 11, R2 at chromosome 2 and p53R2 at chromosome 8 [13] ).
Although protein R1 has a longer life (>24h) when compared to protein R2 (3h), it has been speculated also what would happen with protein R1 if DNA synthesis was not required [14] . Some light was shed, in 1999, by Ghabes et al that found a protein in yeast (named Sml1) that was able to bind to protein R1 and inhibit it. These studies have shown also that Sml1p could bind to the mouse ribonucleotide reductase R1 protein too. However, the inhibition was shown to be less pronounced than in yeast, occurring probably via a different mechanism [15] . RNR is also regulated by allosteric control. This regulatory process is able to inhibit or activate the enzyme whenever it is needed, ensuring a balance of deoxyribonucleotide mono-mores for DNA replication. In 1979 Reichard and Thelander [16] proposed an allosteric cycle from which the activity of the enzyme was dependent. This theory supported the existence of an activity (a-site) and specificity (s-site) sites and correlated the reduction of specific NDPs according to the occupancy of these sites. It was shown that ATP and dATP can bind to both allosteric sites, while dTTP and dGTP bind only to the s-site. Furthermore, ATP stimulates the reduction of CDP and UDP, dTTP stimulates the reduction of GDP, dGTP stimulates the reduction of ADP and dATP serves as a general inhibitor.
A better allosteric control model has been established by Kashlan, Cooperman and Scott since 2001 [17] [18] [19] , where the existence of a third allosteric site is presented, the hexamerization site (h-site). Its exact location has however not been disclosed yet. Besides the correlated reduction of NDPs , this new model takes into account the influence of the allosteric ligand effects on the quaternary structure of RNR. These studies resorted to murine RNR. Within this theory the binding of ATP, dATP, dGTP, or dTTP to the ssite drives the formation of R1 2 dimer (whose monomers are inactive) that complexes with R2 2 dimer generating an active form, R1 2 R2 2 . The binding of ATP or dATP to the a-site drives the formation of a tetramer named R1 4 , that isomerizes into an inactive form named Rl 4b . If the concentration of ATP is sufficiently high it will bind to the h-site which favors the conversion of Rl 4b into an R1 6 hexamer. This hexamer will complex with an R2 6 protein generating an R1 6 R2 6 complex, which is believed to be the major active form of RNR in the cytosol of normal cells in vivo.
Catalytic Mechanism
The mechanism of generation of the radical as well as the reduction pathway has already been extensively studied [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . However, although a great effort is being made toward the understanding of the reactivity of the di-iron cluster and the tyrosyl radical generation and pathway, the overall process still remains elusive, and further studies need to be performed.
The tyrosyl radical of the R2 component is remarkably stable and can exist in the purified enzyme for an extended period of up to one week [32] . This stability comes from the central position of the radical inside the R2 subunit that behaves like a shell and assures its protection from the surrounding environment.
It is supposed that upon substrate binding the catalytic mechanism is initiated by Cys439 once protein R1 receives the radical from Tyr122. The radical located in the R2 subunit is transferred from Tyr122 to Cys439 through ã 35Å long hydrogen bonds network. This pathway and behaviour are however still obscure. Contrarily, the reduction mechanism is better understood. Although apparently simple, this reaction has been shown to occur in a surprisingly complicated sequence of steps (Scheme 2). A set of kinetic [33] , spectroscopic [34] [35] [36] , Xray crystallographic [4, 37] , isotopic labeling [38] , sitedirected mutagenesis experiments [39, 40] , and theoretical calculations [20] [21] [22] 24, 26, 41] have shed some light on the chemical events of the catalysis; the key amino acid residues involved were identified and a five-step hypothesis for the reaction mechanism was proposed. The active site is composed by a set of five aminoacids namely, Cys225, Asn437, Cys439, Glu441 and Cys462 and the radical is allocated at Cy439 (Fig. 3) . In the first step, the 3´-H atom is abstracted by the radical sulfur of Cys439; this is followed by the transfer of a proton from the 3´-OH group to Glu441, with concomitant protonation of the 2´-OH group by Cys225 and elimination of a water molecule; the third step corresponds to the abstraction of an H atom from the thiol group of Cys462 by carbon C2´ -directly or with mediation of the closer Cys225 -; the resulting disulfide radical anion is subsequently reduced to a standard disulfide bond and a proton is transferred from Glu441 to the 3´-O atom, which replaces the charge in the glutamate residue and the spin density in the C3´ carbon; the final step consists of the donation of the H atom by Cys439 back to that carbon; thus, the 2´-deoxyribonucleotide is formed and the essential tyrosyl radical is regenerated. In the end of this process the disulfide bridge is oxidized by Thioredoxin and the enzyme is ready for a new reduction cycle.
A better understanding of the chemical mechanisms involved in normal catalysis is fundamental in order to understand crucial checkpoints that may allow the inhibition of the enzyme. This is important for the rational design of more specific and effective inhibitor compounds.
Several inhibition mechanisms concerning several inhibitors (that are going to be described below) are now better understood. To unravel these puzzling pathways, the available experimental data together with computational methods [20] [21] [22] [24] [25] [26] , particularly quantum chemical calculations and QM/MM calculations have shown to be powerful and valuable tools. The involvement of computational methods allowed structural information of transient events, such as transition states and snapshots of molecules in the act of reaction, that are not possible to detect by normal physical methods. This is particularly important in the case of RNR, in which unstable intermediates such as radical species, are involved.
A review concerning the synthesis of recent work, using computational methods and experimental data, on the action and inhibition mechanisms of class I ribonucleotide reductase (RNR) was performed by Pereira et al. [42] . Scheme 2 shows a diagram where the catalytic mechanism of the natural substrate is compared with the different pathways that are followed by the substrate analogues that induce enzyme inactivity (computationally studied).
RNR INHIBITION
RNR inhibition knowledge is increasing substantially. In the last decade, a considerable increase in the intellectual propriety concerning this enzyme has been observed. Its importance in cancer and HIV therapies has motivated many research groups into the study and development of specific and powerful inhibitors that can inhibit this enzyme.
The variety of inhibitors currently known is extensive [43] and in this review they will be divided in two main groups. The first group includes all the inhibitors that hinder the formation of an active RNR and the second group contains all the inhibitors that only inhibit the enzyme when it is already formed and active. Special attention will be addressed to the first group of inhibitors since they are the latest ones and possibly the next generation of RNR inhibitors. 
Inhibitors that Preclude the Formation of an Active RNR
These inhibitors do not allow the formation of an active RNR. They can be divided in two groups: The first group contains the inhibitors that hinder the translation and therefore the formation of the proteins R1 and R2; the second group contains all the inhibitors that do not preclude the formation of proteins R1 and/or R2 but hinder their dimerization, inactivating the enzyme in this way.
Translation Inhibitors
Translation inhibitors are the new generation of RNR inhibitors. The targets of these inhibitors are certain parts of the mRNA or DNA strand that upon binding prevent the expression of specific genes. The building blocks of these inhibitors are generally ribonucleotides or deoxyribonucleotides, depending on the target molecule (mRNA or DNA respectively). These inhibitors are designed to halt a biological event, such as transcription, translation or splicing.
The common name by which these inhibitors are named is antisense inhibitors and they can be widely found in several cells. In fact, some cells can produce naturally antisense RNA molecules that interact with complementary mRNA molecules and inhibit the expression of certain proteins.
Many forms of these inhibitors have been developed and can be broadly categorized into three main categories, compromising different types of oligonucleotides: The first type of oligonucleotide is the classic antisense compound which compromises short gene-specific sequences of nucleic acids, that has as target specific strands of mRNA that prevent the production of that RNA's protein (Fig. 5-pathway B1) . Some of these antisense compounds have the ability to activate RNase H that allows the antisense to target and bind with another strand of RNA. This process can be repeated over and over, allowing one oligonucleotide to bind with, and destroy, many strands of faulty RNA.
The second type of oligonucleotide is similar to the previous compounds (Fig. 5-pathway B2) . However, instead of using RNase H to destroy the RNA strand which has combined with the antisense, these oligonucleotides block other processes, such as regulatory binding proteins, ribossomes and/or spliceosomes, that hinder mRNA translation. Just as in the classical antisense compounds, this allows a single oligonucleotide to target and bind to numerous strands of RNA.
The third type of oligonucleotide is a triple-helix DNA. Many researchers do not consider this a true antisense compound. The first two types of oligonucleotides target specific strands of RNA to prevent the production of faulty proteins. Triple-helix DNA, however, targets the doublehelix DNA strand itself. These triple-helix oligonucleotides are designed to bind with a specific section of the DNA, preventing its transcription into RNA. Triple-helix oligonucleotides truly serve the same purpose as classical antisense. These oligonucleotides simply attack the problem in a different manner, by preventing faulty proteins even earlier in their production process (Fig. 5-pathway A) .
The potential of the antisense technology was discovered by Zamecnik and Stephenson in 1978 [44], when they found that a tridecamer d(A-A-T-G-G-T-A-A-A-A-T-G-G)
, which was complementary to 13 nucleotides of the 3'-and 5'-reiterated terminal sequences of Rous sarcoma virus 35S RNA, was able to induce the inhibition of virus production. Since then, antisense technology is an attractive alternative for target validation and therapeutic purposes. Its importance gathers more relevance with the completion of sequencing of the human genome and it is estimated that at least 5000 diseases related with genes are potential candidates for antisense therapy. Currently, the antisense therapies are under evaluation as therapeutic agents for a variety of diseases, including cancer [41, 45] and AIDS [46] , and the FDA has already approved a phosphorothioate antisense oligonucleotide, fomivirsen (Vitravene TM ), for human therapeutic use [47] .
One of the major challenges for antisense approaches is the stabilization of oligonucleotides, since unmodified oligonucleotides are rapidly depredated by biological fluids and in cells by both exonucleases and endonucleases. In early stages, the antisense backbones were made from natural genetic materials and linkages [48] . These compounds were easily degraded or broken down by enzymes in the blood and within cells, and had difficulty crossing cellular membranes to enter the cells that contained their genetic target. Subsequently, modified backbones were designed, which resist degradation by enzymes, and provide enhanced entry to tissues and cells. In fact several companies are working in this field, e.g. Isis Pharmaceuticals that has an impressive patent portfolio built upon its ability to synthesise modified oligonucleotides in large amounts [49] . In general, three types of modifications can be distinguished: altered phosphate backbones, analogues with un-natural bases and analogues with sugars (especially at the 2´ position of the ribose). These groups of modifications are normally known as first, second and third generation of oligonucleotides, respectively. A comprehensive review dealing with the antisense-oligonucleotides modifications and their respective patents was made by Jens Kurreck [50] .
Proteins R1 and R2 from RNR are encoded in different chromosomes. In humans, the R1 gene has been mapped to chromosome 11, band p15, [51, 52] and the R2 gene in chromosome 2 [9] . Interestingly, it was found that the R2 gene is composed by two promoters which produce two major mRNAs with 5´-untranslated regions (50-UTRs) of different lengths [53, 54] . However, it is unknown whether both mRNA species can be translated and how their translations are regulated.
Several studies have been addressed to RNR genes in order to preclude their transcription. For example, in 2000, Chen and co-workers [55] reported that antisense oligonucleotides could be successfully used to inhibit human cancer cell growth by the translation inhibition of both RNR subunits. The study involved the incubation of human oropharyngeal KB cells with human antisense oligonucleotides of both subunits, R1 and R2, by isopropylthiogalactose. Although it was observed that the antisense of subunit R1 does not reveal a significant inhibition of the cell growth, the antisense of subunit R2 was capable of decreasing the formation of subunit R2, thus reducing the enzyme activity and inhibiting cell growth. In the same year Aurelian et al. [56] reported that in the case of the herpes simplex virus, type 2, the growth and latency reactivation by cocultivation could also be inhibited by RNR inactivation with antisense oligonucleotides, but in this case complementary to subunit R1 from RNR. GTI-2040 is a 20-mer phosphorothioate oligonucleotide complementary to the mRNA of the R2 subunit of RNR. in vitro GTI-2040 decreases mRNA and protein levels of R2 in a sequence-and target-specific manner. When GTI-2040 is used in vivo, as monotherapy, it promotes a highly significant reduction in tumour growth in all nine human cancers tested to date in animal models [63] . In the preclinical toxicology program, no major clinical toxicity has been observed to date. The significant antitumor activity against many different human tumors observed in preclinical studies has promoted this drug to Phase I clinical trial in the U.S., which has already been successfully completed [64] .
GTI-2040 is currently the subject of a clinical trials agreement with the United States National Cancer Institute (NCI) under which GTI-2040 is being tested in combination chemotherapy in six different clinical trials. A Phase II study of GTI 2040 in combination with chemotherapy for the treatment of renal cell carcinoma was recently completed. In this study of late stage patients, 52% of the patient population displayed disease stabilizations with few unexpected side effects and tumour regressions were observed in some patients.
The patent application for this antisense drug has been filed in numerous additional international jurisdictions, e.g. Canada, Europe, United States, Singapore, Australia and New Zealand [58, 59] .
GTI-2501 is a 20-mer oligonucleotide that is complementary to a coding region in the mRNA of R1, the large subunit of RNR. When compared with GTI-2040, GTI-2501 has produced similar results in animal models for a broad range of human cancers and has produced complete tumour regression in all animals in two human cancer models (breast cancer and renal cell carcinoma) [65] . in vitro Studies have demonstrated that GTI-2501 decreases mRNA and protein levels of R1 in a sequence-specific and dose-dependent manner. in vivo Studies have shown that GTI-2501 significantly inhibit the growth of standard mouse models with a variety of different human cancers (lung, liver, ovary, brain, melanoma, breast and pancreatic tumor). This inhibitor has shown specific inhibition of metastasis of human melanoma cells to the lungs in CD-1 athymic nude mice and prolongs the survival of mice bearing human lymphoma To date, GTI-2501 has concluded a Phase I clinical trial, and is currently in a Phase II clinical trial, in combination with docetaxel for the treatment of prostate cancer. Initial testing of GTI-2501 demonstrated strong antitumor activity in preclinical studies of prostate cancer and a variety of other human tumor types. With respect to patents, GTI-2501 is under evaluation in the United States and Europe.
The latest developments of antisense technology allow the conclusion that the inhibition of RNR can be performed in a pre-translation phase, which has several advantages over the other types of inhibition: i) it becomes very specific for the corresponding mRNA of that protein and therefore of each organism, and ii) taking this specificity into account it may decrease the toxicity or even the number of secondary effects that normally follows the other kind of inhibitors [66] .
Dimerization Inhibitors.
The dimerization inhibitors prevent the complexation of two or more proteins that are crucial for the enzyme activity. In RNR, these inhibitors bind very tightly to protein R1 precluding the complexation with protein R2 [67, 68] . As a result, the enzyme becomes inactive. These inhibitors are peptides, non-peptides or peptidomimetics with similar sequences to the flexible C-terminus of subunit R2, which is responsible for interaction with the R1 subunit [69, 70] ( Table 2) . Dimerization inhibitors that are able to disrupt RNR quaternary structure still remain an attractive goal in RNR inhibitory research [69, 71] . The main advantage in these kind of inhibitors is the little homology of the R2 CTerminus within different organisms. This allows specific inhibition of a parasite RNR without interfering with the host RNR [72] . Some examples of this feature were demonstrated by Chabes et al. [15] in which the Sml-1 protein was shown to be an efficient physiological inhibitor of RNR in yeast, whereas in mammalians, it is poorly effective.
RNR dimerization inhibitors were pointed out for the first time by Dutia et al. in 1986 [73] . They found that the interaction between the large and small subunits (subunits R1 and R2, respectively) of Herpes simplex virus (HSV) is highly conserved [54] . Furthermore it was shown that, in vitro, it was possible to bind a synthetic peptide that interferes with the complexation of both subunits and from which resulted the enzyme inactivity [74] . The nonpeptide YAGAVVNDL, corresponds to the carboxyl-terminal region of HSV-R2. The interest with these inhibitors increased shortly after because this inhibitor is specific to RNRs of all herpesviruses studied to date (because their R2 carboxyl terminus are homologous) but substantially different from those of other species [75, 76] .
However, evaluation and use of this nonpeptide as a potential antiviral agent in vivo has not been possible, presumably because the peptide is too large to enter eukaryotic cells. Nevertheless, these findings attracted the attention of several investigators that started to perform detailed structure analysis [77, 78] including NMR studies [79] and mutagenic experiences [80] [81] [82] , that allowed the extrapolation of new conclusions. For example, these studies allowed concluding that the complementarity of the peptide is not absolutely required and several group substitutions in the five C-terminal residues, along with combination of large hydrophobic groups at the N-terminus, optimize the inhibitory effect.
The first patent concerning these type of inhibitors was made by R. Friedinger et al. in 1987 [83] . Merck continued these studies and have subsequently showed that the shortest peptide that is able to inhibit the activity of Herpes simplex virus RNR in vitro, (VVAAL), could be modified to build longer peptides with the same rate of inhibition [84] .
in vivo Studies with some of the inhibitors developed by Moss et al. [85] , were even more stimulating since the inhibition was able to effectively reduce the severity of the virus in most of the cases, without interfering with the infected host. From this group of inhibitors BILD 1357 (Fig.  6 ) has shown to be the most potent antiherpetic agent (in fact, the most potent dimerization inhibitor known till today) and the pentapeptide H-Val-Val-Asn-Asp-Leu-OH showed promising properties since it was able to increase the inhibition potency up to 4000 times. Although most of studies were performed with the Herpes simplex virus, some work has also been done with other organisms, such as mammalian [75] , E. coli, M. tuberculosis and S. cerevisiae. Some of these inhibitors are represented in Table 2 and are compared with the R2 Cterminus of the corresponding organisms. The first patent concerning peptides that were able to inhibit mammal RNRa was reported by Guindon et al. in 1991 [86] . In this report it was shown that the C-terminal of R2 is very similar within mammals, but very different from the viruses. This was a great achievement since the difference between the RNR sequences can lead to the inactivation of the parasite virus without interfering with the host cells.
Taking into account the results obtained with the Herpessimplex virus, several systematic structure-function studies [87] , including residues modification and deletions [88, 89] , were also performed with these organisms in order to understand the inhibition mechanism and to achieve better inhibitory activity. These studies led to the conclusion that for inhibition it is only necessary a small peptide and that the acetylation [76] of these inhibitors improves, in most of the cases, ligand affinity and therefore the inhibition efficacy. Together with NMR trNOE techniques studies [90, 91] , it was also observed that there are two crucial phenylalanine residues upon which the inhibitory activity is dependent (Phe 1 and Phe 7 ). Pender et al. [88] showed that these Phe residues interact with two distinct positions in subunit R1 with which they have dominant interactions, the F7 subsite which is narrow and deep and very specific for Phe groups (Phe1), and the F1 subsite, a shallow and broad subsite that can satisfy a wide range of groups and interacts strongly with Phe7.
Another kind of studies was performed by Gao [92, 93] with small molecules. He found that Fmoc-tripeptides (Fmoc: a-fluorenylmethyoxycarbonyl) were also capable of inhibiting the dimerization of the mammalian RNR subunits. The inhibition was shown to occur in both subunits and with higher affinity than with the R2 C-terminus polipeptide derivatives. It was also shown that these molecules bind to another site in addition to the ones targeted by the R2 Cterminus peptide derivatives. Although its precise location is still unclear, the fact that these inhibitors strongly inhibit only the R1 2 R2 2 form and not the R1 6 R2 6 form, suggests that it may be located on a part of the R1 surface that becomes unavailable for binding after hexamerization [94, 95] .
In 1991, Guindon [86] et al. showed that several peptides were indicated for preventing or ameliorating abnormal cell proliferation.
Cooperman from the University of Pennsylvania has patented a composition of linear peptides, cyclic peptides, peptide analogs, and peptidomimetics that successfully inhibit ribonucleotide reductase enzymes from mammalians [96] . This composition has shown to be a valuable tool in the treatment of cancer, viral and bacterial infections.
These studies were also extended to some procaryotes (M. tuberculosis, Plasmodium falciparum and E. coli) and fungi (S. cerevisiae) [87, 90, 97] . Although it was observed that RNR inhibition could also be accomplished by mimicking the R2 C-terminal sequence, the conclusions acquired from some eukaryotes and Herpes simplex virus could not be directly applied to some of these organisms. For example, although in M. tuberculosis and S. cerevisiae the acetylated R2 C-terminus heptapeptide maximizes the inhibitory efficacy, as in eukaryotes, in E. coli it has the opposite effect [68] . Moreover in E. coli the peptides must be longer since the two sites of the R2 C-terminus peptide that interact with R1 are not contiguous, contrarily to what happens with mammalians [98] . A patent concerning these inhibitors was published in 1988 by Dobrogosz et al. where the inhibition of bacteria, yeast and protozoa was reported with success [99] . Another patent concerning several oligopeptides that are indicated to prevent bacterial infections was published by Rakhit in 1992 [100] . In 1995, Cooperman have also shown that compounds comprising peptides derived from the C-terminus sequence of the R2 subunit from Plasmodium falciparum could hinder its activity. This has shown to be particularly useful in the prevention and treatment of malaria caused by Plasmodium. falciparum [101] .
Recent work has pointed out that in the murine RNR some small hydrophobic peptides are much more effective as inhibitors of R1 2 R 2 than of R1 6 R 6 . This raises important questions and these inhibitors must be checked to see if the Nevertheless this point is important because, for instance, in tumour cells where the ATP concentration is very low (and where the R1 2 R2 2 form is more expressed), the action of specific R1 2 R2 2 inhibitors may be an advantage [102, 103] .
Inhibitors that Preclude Enzyme Activity
These inhibitors interact with the enzyme and inhibit its function either by destroying the radical that is lodged in subunit R2 or inactivating subunit R1, which normally leads to the formation of adducts with a characteristic absorption band in the UV/visible spectra.
Since most of the inhibitors have R1 or R2 as a specific target, these inhibitors are divided in two groups too: specific R1 binding inhibitors that bind directly at subunit R1 and can inhibit one or both subunits, and specific R2 binding inhibitors, that bind directly and inhibit subunit R2.
Specific Binding R1 Inhibitors
These inhibitors interact specifically with subunit R1, but can also inhibit protein R2 in some cases. The first inhibitors were produced taking into account RNR allosteric regulation (Table 3) . Therefore, several changes to nucleoside triphosphates were induced to this type of molecules in order to interfere with enzyme activity. This was a challenging process since the substrates of the allosteric control had to compete with the products of the catalytic process. Nevertheless, it was shown by Harrington et al. [104] that RNR tolerates a wide range of modifications on the ATP molecule, including changes in the nucleobase, sugar and phosphate linkages, either in the allosteric or catalytic sites.
It was found that some of the modified molecules could activate the enzyme as efficiently as ATP e.g., 3-deazaATP or 5'-adenylimidodiphosphate and some analogues were capable of inhibiting RNR. In this group we can find several analogues of deoxyadenosine, such as 2-chloro-2'-deoxyadenosine (clarabine-brand name LEUSTATIN®), developed by Ortho Biotech, 9-beta-D-arabinofuranosyl-2-fluoroadenine (fludarabine -brand name Fludara®) developted by Schering AG, and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (clofarabine), developed by Genzyme Corp. in the US and by Bioenvision in Europe.
Cladribine has been known since the 1960's as an intermediate for the synthesis of 2-deoxynucleotides and its potential for the treatment of leukaemia was disclosed in 1984. It is now used to treat a type of blood cancer known as hairy cell leukaemia [105, 106] . Cladribine was synthesised by Christensen et al. [107] and was launched by Ortho Biotech in collaboration with The Scripps Research Institute [108, 109] . This Institute and the Johnson & Johnson group hold several patents claiming preparation methods, and additional indications, such as multiple sclerosis and rheumatoid arthritis [110] . Fludarabine is distributed by Berlex Laboratories, and over the past decade, has become an effective agent for the treatment of lymphatic disorders (chronic lymphocytic leukaemia, prolymphocytic leukaemia and indolent non-Hodgkins lymphoma) [111] [112] [113] . Clofarabine is developed by Bioenvision Inc., and has been shown to be powerful in the treatment of acute and chronic leukemias, as well as other hematological malignancies, and solid tumours.
From these analogues, Clofarabine combines many of the favourable properties of the two most commonly used Cl nucleoside analogs, fludarabine and cladribine, but has several-fold greater potency of damaging the DNA of leukaemia cells when compared to fludarabine. Clofarabine appears to achieve this greater potency by a process of breaking DNA chains besides inhibiting ribonucleotide reductase. Clofarabine distinguishes itself from other drugs by its broader activity, in particular the way in which it damages the cells mitochondria and initiates the process of programmed cell death (apoptosis) [114, 115] .
A major problem associated to the effectiveness of these kind of inhibitors is their half-life since, when in excess, they are degraded by adenosine deaminase.
The studies involving these inhibitors have also shown that besides RNR, several enzymes [116, 117] that are involved in DNA replication and repair, can also tolerate a wide range of modifications on the nucleoside triphosphates. Some of the analogues can even hinder their activity and in many cases they can be found incorporated in DNA during the S phase.
Recently, it was exposed by Hoffer et al. that allosteric regulation of RNR in T. brucei differs from the mammalian one, which gives hope for the use of allosteric inhibitors in the selective inactivation of parasite RNRs.
Although good results have been obtained with the allosteric and others inhibitors the most popular inhibitors are the substrate analogues. The latter are normally known as suicide inhibitors because they are recognized by RNR as normal substrates and react in the active site leading to abnormal products that inactivate the enzyme ( Table 4) . Most of these inhibitors are administrated as pro-drugs and must be activated previously by deoxycytidine kinase (dCK) to become a substrate analogue of RNR.
Most substrate analogues differ, from the natural one, in the group that is attached to carbon C-2´, since this is the position that is reduced during RNR catalysis. Nevertheless, and similarly to the alosteric binding sites, it was found that the RNR catalytic active site tolerates a wide range of modifications, either on the ribose ring or in the position C-3´ of the nucleotide triphosphate.
One of the first inhibitors of this kind was ara-C (arabinosylcytosine or also called as Cytarabine), a nucleotide analogue with an arabinose instead of a ribose ( the hydroxyl group attached to carbon C-2´ is on the other face of the ring) that is developed by Pharmacia & Upjohn. This inhibitor proved to be a potent drug for the treatment of acute non-lymphocytic leukemia in adults and pediatric patients and was approved by the FDA in 1969. Besides inhibiting RNR, it also competes with dCTP, for incorporating with DNA, resulting in a block of DNA synthesis and it further inhibits the function of DNA polymerase α and β. Its main disadvantage is concerned with its rapid degradation by deamination and the ineffectiveness against solid tumors. Interestingly, in order to avoid these disadvantages several modifications were induced to the ara-C which lead to the appearance of new products such as fludarabone and cladribine as (described before).
Taking these results into account, novel 2´-substituted substrate analogues started to be synthesized and their antitumour activity has been intensively investigated in the hope of finding an effective inhibitor. Some examples are 2´-chloro-2´-deoxynucleoside-5´-diphosphates (CldNDP) and 2´-azido-2´-deoxynucleoside-5´-diphosphates (N 3 dNDP), which activity was first studied by Thelander and Larsson in 1976, and 2´-deoxy-2´-fluoro-nucleoside-5´-diphosphates (FdNDP) studied in 1980 by Stubbe and Kozarich. These inhibitors have a similar mechanistic behavior, and yield a common final product, a ketodeoxyribonucleotide, that leaves the active site, and in solution leads to the formation of a furanone derivative that adds covalently to subunit R1 of RNR (probably to a lysine residue), forming a chromophore with a characteristic UV absorption band. The appearance of this band is normally a consequence of the enzyme inhibition. Within these inhibitors, R2 subunit is also inhibited since after the formation of the ketodeoxyribo-nucleotide the radical becomes lodged at a nitrogen bonded to Cys225 of the active site, precluding tyrosyl radical regeneration.
A similar inhibitor is CH 2 dNDP that shows high resistance to cytidine deaminase, and for which the process of inhibition is believed to be similar, involving the formation of a 2´-methyl furanone derivative. Although these inhibitors have shown good results in in vitro and some in vivo studies, it was found that the inhibition is precluded by the presence of reductants such as thioredoxin, dithiothreitol (DDT) or glutathione that are able to intercept the furanone derivative.
(E)-2´-Fluoromethylene-2´-deoxycitidine-5´-diphosphate or recently named Tezacitabine (CHFdNDP) is another RNR inhibitor [118] . It was developed by Chiron BioPharmaceuticals but it was acquired in January of 2002 by Matrix Pharmaceutical Inc. This inhibitor is able to inactivate both RNR subunits and has shown potent chemotherapeutic efficacy against leukemia and solid tumours [119] . EPR and theoretical studies suggested that the loss of the tyrosyl radical is accompanied by the addition of a substrate analogue to an active site residue (probably a cysteine) which leads to the formation of a chromophore with λ max of 334 nm. Unlike the previous inhibitors, the presence of reductants, such as dithiothreitol does not protect the enzyme against inactivation by CHFdNDP, since the substrate analogue binds to the enzyme while it is inside the active site.
Beyond RNR inhibition, some of the substrate analogues are also capable of inhibiting RNA synthesis and/or human DNA elongation, either by their incorporation into the DNA or inhibiting DNA replication. For instance, 2´-deoxy-2´,2´-difluoro-cytidine-5´-diphosphate (F 2 dNDP) and 2´-deoxy-2´-methylene-nucleoside-5´-diphosphate (CH 2 dNDP) inhibit RNR, (but in a different phosphorilation state), and are also able to interact with other enzymes that metabolize ribonucleotides and deoxyribonucleotides such as nucleoside and nucleotide kinases, CTP synthethase and DNA polymerases.
2´,2´-difluoronucleosides have been shown to exhibit antiviral effects in vitro and oncolytic activity in standard cancer screens [120] .
Another possible RNR inhibitor is 2'-cyano-2'-deoxyarabinosylcytosine (CNdNDP). The inhibition effect under RNR is still not known but it is known to delay the progress of further DNA replication similarly to what happens with gemcitabine (F 2 dNDP) and other deoxycytidine analogues. However, whereas in gemcitabine the incorporated analogue competes with the natural deoxytidine 5'-triphosphate for incorporation into the replicating DNA, leading to DNA synthesis inactivation at the S phase, CNdNDP also induces DNA strand breaks by a β-elimination-mediated mechanism, that leads to cell cycle arrest at the G2 phase.
Another kind of RNR inhibitors are the substrate analogues substituted at carbon C-3'. Although less popular there are several compounds of this type. It was suggested that these inhibitors were able to trap the thiyl radical located at Cys439 that is proposed to initiate the reaction, thus quenching the tyrosyl radical and therefore inhibiting RNR. From Matsuda et al. [121] studies, it was suggested that ethynyl nucleoside analogues could act as inactivators of RNR, since they share potent anti tumour activity, both in vitro and in vivo. However, more studies need to be accomplished with the enzyme in vivo and in vitro.
As pointed out before, nitric oxide is also an inhibitor of RNR. Taking this idea into account, another class of substrate analogues that are capable of generating NO
• was developed by Fallois et al. These inhibitors have S-nitro groups attached to carbon C-2´ that spontaneously decompose into nitric oxide, and are capable of inhibiting RNR in both subunits. Although the inhibition with NO is reversible, the remaining radical sulphur of the substrate can interact with the reducing cysteines of the active site and thus modify the course of the reaction, inhibiting irreversibly RNR in subunit R1.
The same group also reported the synthesis of 2'-deoxy-2´-mercaptouridine 5´-diphosphate, a substrate analogue substituted in carbon C-2´ with a SH group, that has been shown to be an efficient inactivator of RNR. The proposed mechanism is still under research [122] but it is known that in the presence of oxygen there is an irreversible inactivation of protein R2 concomitant with the formation of a perthiyl radical (RSS*), whereas in the absence of oxygen no inhibition is observed. This new radical is believed to be located in a cysteine residue of subunit R1, probably in Cys225. Interestingly, the perthiyl radical does not lead to R1 inactivation, suggesting that the presence of reductants such as thioredoxin can regenerate oxidized active site cysteines, as it happens with the natural substrate.
Specific R2 Binding Inhibitors
The target of these inhibitors is protein R2, and from the inhibition results: i) the destruction of the radical that is settled in the tyrosine residue (radical scavengers) or ii) the inactivation of the radical preventing its generation by chelating the iron of the binuclear cluster (iron chelators) ( Table 5) .
As the radical is buried c.a. 10Å from the surface of the protein, these kind of inhibitors are generally small and planar molecules in order to facilitate their approach to the free radical.
The first inhibitor of this kind that was able to preclude RNR activity was hydroxyurea. Its chemical name is hydroxycarbamide and is trademarked by the commercial name of Hydrea and Droxia®, by Bristol-Myers Squibb Company (BMS).
Hydroxyurea (HU) first started to be investigated, as an antineoplastic agent in humans, in the 1960's. Its synthesis involved many complex crystallization steps [123] , but today it is a simple synthesis reaction involving hydroxylamine, HCl and KCN.
This compound is cell cycle phase-specific (S-phase) and acts primarily as an inhibitor of RNR. It has already been indicated by the FDA for the treatment of a variety of cancers, e.g., chronic myeloide leukemia, polycythemia vera and hypereosinophilic syndrome. Although its anti-tumor activity is still controversial [124] [125] [126] [127] , it is a fact that is able to promote temporary remissions in metastatic malignant melanomas and other solid tumors like carcinomas of the head, neck, genitourinary systems, cervix, and lung. Moreover, it has been recently proposed for the treatment of sickle cell anemia and possibly AIDS [128] [129] [130] . In small studies combining hydroxyurea with Zerit (d4T) and Videx (ddI), there was noticeable anti-HIV activity [131] .
The exact mechanism of HU is still obscure, but it is known to react with the di-iron centers [132] . In fact, it is able to destroy the essential tyrosyl free radical of RNR, turning the enzyme inactive, and therefore consequently stop DNA synthesis.
The most serious side effects of hydroxyurea involve the decrease of blood cells (anemia) [133] , platelets (thrombocytopenia) [134] , and white blood cell counts (leukopenia, neutropenia [135] ), which can decrease patient resistance to infections.
Radical scavengers similar to hydroxyurea [136] such as acetohydroxamate [137] , substituted benzohydroxamic acids [138] or even hydroxylamine, hydroquinones and hydrazine derivatives [139] have shown similar inhibition behavior and some of them have shown to be more potent and/or less toxic than hydroxyurea [140, 141] . Nevertheless, hydroxyurea is still the one that has been more used in cancer therapy.
Since good results were achieved with these inhibitors, similar types of approaches were tried in order to inhibit the enzyme. The iron chelators were the next generation of inhibitors that have shown good properties. These inhibitors are able to bind very tightly to metal ions and form chemically inert complexes, inhibiting the formation of the crucial radical [142] . In addition, many studies have demonstrated that numerous cancer cells types are more susceptible to the effect of the chelators than normal cells.
Several iron chelators such as pyridoxal isonicotinoyl hydrazone (PIH), deferoxamine, and thiosemicarbazone derivatives inhibit enzymatic activity, either by chelation of the cofactors, which precludes the incorporation of the cofactor in the enzyme or directly at the enzyme-bound metallic centre. The success of these iron chelators, particularly DFO (Deferrioxamine mesylate), Triapine (3-aminopyridine-2-carboxaldehydethiosemicarbazone) and 2-hydroxy-1-naphthylaldehydeisonicotinoyl hydrazone [143] , in vitro, in vivo and in some clinical trials, together with their selective antitumour activity, confirm their potential as anti cancer drugs.
Triapine has been developed by Vion Pharmaceuticals, Inc., and has demonstrated a broad spectrum of activity in animal tumor models [144, 145] , showing efficacy in both in vivo and in vitro tests and an ability to inhibit tumor cell growth in the murine L1210 leukemia, murine 109 lung carcinoma and human A2780 ovarian carcinoma models. Tests indicate they are between 65 and 1000 times more potent than FDA's approved Hydroxyurea. Moreover, testing has shown activity against cell lines resistant to Hydrea and Gemzar (see below), which are approved agents for the treatment of cancer. DFO (desferrioxamine methane sulphonate), developed by Novartis Pharma (brand name Desferal), is a chelating agent used world-wide in the treatment of iron overload conditions, such as hemochromatosis and thalassemia. Desferal is capable of taking up free iron, either in plasma or in cells thereby forming the complex ferrioxamine however, it does not remove iron from transferrin or from hemoglobin or from other heme containing substances. Desferal can also immobilize and chelate aluminum [146, 147] . However, DFO has some serious disadvantages, including high cost, limited membrane permeability, and long subcutaneous administrations.
Pyridoxal isonicotinoyl hydrazone derivatives (PIH) are tridentate chelators and relatively non-toxic drugs, economical to synthesize, orally effective and with high selectivity and affinity for iron. They could be used not only in the treatment of iron overload, but seem to be also effective in the therapy of free radical-mediated injury, malaria and as anti-proliferative agents in some types of cancer. Richarson [148, 149] and Ponka [150] demonstrated that some chelators of the pyridoxal isonicotinoyl hydrazone class have antiproliferative activity that is far greater than desferrioxamine (DFO).
The progress in the development of orally effective iron chelators such as PIH has been painfully slow since these agents are not proprietary (patentable) and therefore their attractiveness for drug industry is severely limited.
Recently, it was also found that the enzyme is rather susceptible to NO
• [151] . Studies in vitro with several thionitrites, e.g. SNAP (S-nitroso acetylpenicillamine) manufactured by Alexis Biochemicals, have shown that these NO
• donors can inhibit RNR [152] , quenching the tyrosyl radical, presumably by forming nitrosotyrosine adducts. However, these adducts have shown to be reversible, which affects the inhibitor efficiency. The reversible behavior should be related with the fact that NO
• is also produced physiologically, which suggests that this interaction has an important biological role in the cell regulation.
CURRENT & FUTURE DEVELOPMENTS
Up until now the demise of cancer has relied on surgical resection and the inhibition of tumour cell proliferation, using ionizing radiation or chemotherapeutic drugs designed to perturb DNA synthesis or the mitotic event. The development of RNR inhibitors is a new hope since it has already shown improvements in the treatment of leukemia, lymphoma, testicular cancer and many other solid tumor types.
Over the last two decades, it has been observed a great increase in the development of potent RNR inhibitors using different strategies. At the same time, important structureactivity relationship studies allowed to point out crucial information that is being used in order to get more efficient substitutions in the general structures of the RNR inhibitors. According to the analysed data, the new generation of inhibitors directed at antisense technology seems to be the most promising one. These inhibitors show many advantages over the others, e.g, rational efficiency in drug design, since they allow shorter timelines to identify lead drug candidates in the discovery phase of the development as well as reducing the potential for failure in the early stages of development. Furthermore, the rules for creating these drugs are known, the chemistry is constant, and the only modification is the order of the drug's nucleotides, in order to turn the drug target specific. Moreover, the distribution and metabolism of antisense drugs are very similar from drug to drug, resulting in a common and often predictable safety profile across antisense drugs. Dimerization inhibitors have also been showing promising results, since they can inhibit parasite RNRs without interfering with the host RNR. This specific inhibition is already in use and has been showing to be a valuable tool in the treatment of anti-viral and anti-bacterial diseases. Substrate analogues inhibitors, e.g. gemcitabine and fluoromethylene, that have already been approved by the FDA in the treatment of several kinds of tumour, (as it happened with hydroxyurea) cannot be disclosed from this list. These inhibitors have been in use for longer and successfully employed in several treatments of cancer. However, the toxicity and the inexistence of specificity is a problem with these kind of inhibitors.
Although a great success is being observed with RNR inhibitors, there are two problems that researchers have been facing with: i) the first is the toxicity of the inhibitors, that requires a careful balance between the toxicity of normal tissues vs cancer cells in order to acquire the desired effect;
ii) the second is the resistance to RNR inhibitors that has been observed in several treatments during therapy [153] .
The challenge of RNR inhibition now resides in the development of safer and more efficacious inhibitory compounds, which will be surely available soon, taking into account the high potency of the enzyme and the available data.
